Nathan Bahary

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations

Medicine, Oncology, Pharmacology +13

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma

Benjamin J. Raphael, Ralph H. Hruban, Andrew J. Aguirre et al. · Cancer Cell · 2017 · 2.1K citations · Full text

Medicine, Genetics, Molecular Genetics +13

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison et al. · Journal of Clinical Oncology · 2015 · 544 citations

Medicine, Oncology, Pharmacology +17

The cloche and spadetail Genes Differentially Affect Hematopoiesis and Vasculogenesis

Margaret A. Thompson, David G. Ransom, Stephen J. P. Pratt et al. · Developmental Biology · 1998 · 507 citations · Full text

Life Sciences, Developmental Biology, Genetics +17

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 487 citations

Medicine, Oncology, Pharmacology +17